Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose tirofiban in ST-segment elevation myocardial infarction

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 10, 2009, Pages 1612-1618

  Heestermans, A A C M ^a   Van Werkum, J W ^b   Hamm, C ^c   Dill, T ^c   Gosselink, A T M ^d   De boer, M J ^d   Van houwelingen, G ^e   Hoorntje, J C A ^d   Koopmans, P C ^f   Ten berg, J M ^b   Van 't hof, A W J ^d  

^a Location Alkmaar   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c KERCKHOFF HEART CENTER   (Germany)

^d Isala klinieken ^*  (Netherlands)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

^f Diagram BV   (Netherlands)

Author keywords

Glycoprotein IIb IIIa receptor inhibitors; Myocardial infarction; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ASPERGIC; CLOPIDOGREL; HEPARIN; PLACEBO; TIROFIBAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; EMERGENCY CARE; EVENT FREE SURVIVAL; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REPEAT PROCEDURE; RISK REDUCTION; ST SEGMENT ELEVATION; STENT THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ASPIRIN; CORONARY THROMBOSIS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STENTS; THROMBOLYTIC THERAPY; TICLOPIDINE; TYROSINE;

EID: 70350031284     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03573.x     Document Type: Article

References (20)

1. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993, 328:680-4.
2. Zijlstra F, Hoorntje JCA, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, van 't Hof AWJ, Suryapranata H. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999, 341:1413-9.
3. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002, 346:957-66. Controlled Abciximab Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators
4. Smit JJJ, van 't Hof AWJ, de Boer MJ, Hoorntje JCA, Dambrink JHE, Gosselink ATM, Ottervanger JP, Kolkman JJ, Suryapranata H. Incidence and predictors of subacute thrombosis in patients undergoing primary angioplasty for an acute myocardial infarction. Thromb Haemost 2006, 96:190-5.
5. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY trandomized trial. JAMA 2008, 299:1788-99. Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) investigators
6. van Werkum JW, Heestermans AACM, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, Koolen JJ, Brueren BR, Dambrink JHE, Hautvast RW, Verheugt FW, ten Berg JM. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009, 53:1399-409.
7. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol 2007, 50:573-83.
8. Wenaweser P, Rey C, Eberli FR, Togni M, Tüller D, Locher S, Remondino A, Seiler C, Hess OM, Meier B, Windecker S. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005, 26:1180-7.
9. Chechi T, Vecchio S, Vittori G, Giuliani G, Lilli A, Spaziani G, Consoli L, Baldereschi G, Biondi-Zoccai GG, Sheiban I, Margheri M. ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol 2008, 51:2396-402.
10. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126-30.
11. van Werkum JW, Heestermans AACM, de Korte FI, Kelder JC, Suttorp MJ, Rensing BJ, Zwart B, Brueren BR, Koolen JJ, Dambrink JHE, van 't Hof AWJ, Verheugt FW, ten Berg JM. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation 2009, 119:828-34.
12. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358:2218-30. HORIZONS-AMI Trial Investigators
13. van 't Hof AWJ, ten Berg JM, Heestermans T, Dill T, Funck RC, van Werkum JW, Dambrink JHE, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008, 372:537-46. Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group
14. van 't Hof AWJ, Hamm C, Rasoul S, Guptha S, Paolini J, ten Berg JM. Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroInterv 2007, 3:371-80. on behalf of the On-TIME 2 investigators
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-51. Academic Research Consortium
16. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Büttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005, 111:2560-4.
17. Heestermans AACM, van Werkum JW, Taubert D, Seesing TH, von Beckerath N, Hackeng CM, Schömig E, Verheugt FW, ten Berg JM. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008, 122:776-81.
18. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB, Ohman EM, Stone GW. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007, 49:1362-8.
19. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-15. TRITON-TIMI 38 Investigators
20. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schömig A, Kastrati A. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008, 51:690-7.